Klas m otutu ogwu nke JYMed mere ịrịba ọganihu, Laipushutai na-atụ anya na-akpa akara nke UC ọgwụ ọjọọ.

On June 29, 2017, mmepe nke Laipushutai, klas m otutu na nkà mmụta ọgwụ na-akwado mkpebi mmepe nke JYMed na Guangzhou Linkhealth Medical Technology Co., Ltd., mere ka ịrịba ọganihu. The ọgwụ na-IND nkwupụta e nabatara CFDA.

JYMed na Guangzhou Linkhealth Medical Technology Co., Ltd. ruru a imekọ ihe ọnụ nkwekọrịta na 2016 ka jikotara aka ịzụlite ngwaahịa a na China. The umu dechara POC Clinical ọmụmụ na EU na-enweta ezi nchekwa na ngbaghara udu. Ma ndị FDA na EMA aghọta na nke a umu nwere ike etinyere maka ọgwụgwọ na m / II akara, na-ebute ụzọ ga-enye ahụ efe na ọgwụgwọ nke ọrịa na-agafeghị oke ọnyá afọ na ndị na-adakarị ọnwụnwa nke CFDA.

Ọnyá afọ (UC) bụ a-adịghị ala ala, na-abụghị kpọmkwem mkpali ọrịa na pụtara na ikensi na colon. Dị ka ọnụ ọgụgụ, omume ọnụego nke UC bụ 1.2 ka 20,3 ikpe / 100,000 mmadụ kwa afọ na njupụta nke UC bụ 7.6 ka 246,0 ikpe / mmadụ 10,000 kwa afọ. The omume nke UC bụ ihe nkịtị na-eto eto. The UC ahịa nwere nnukwu ọnụ ọgụgụ na ina ọgwụ ọjọọ, na ga-anọgide na-enwe a elu ibu na-emekarị na-eme n'ọdịnihu. N'ihi ya, anya, UC mbụ akara ọgwụ na tumadi dabeere mesalazine na homonụ, na nke abụọ-akara ọgwụ ọjọọ na-agụnye immunosuppressants na ndu monoclonal-alụso ọrịa ọgụ. Mesalazine nwere a ahịa olu nke 1 ijeri China na US $ 2 ijeri na United States na 2015. Laipushutai nwere a mma nzaghachi UC mgbaàmà, na bụ odi mfe karịa na nke ugbu a mbụ akara ọgwụ ọjọọ. Ọ nwere ezi ahịa uru na-atụ anya na-abụ a mbụ akara UC ọgwụ.

333661

 


Post oge: Mar-02-2019
WhatsApp Online Chat!